RESEARCH - Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis

[Guest guest]

Ann Rheum Dis. Published Online First: 19 August 2008.

doi:10.1136/ard.2008.094516

--------------------------------------------------------------------------------

Concise Report

Strontium ranelate reduces the risk of vertebral fracture in young

postmenopausal women with severe osteoporosis

Christian Roux 1*, Jacques Fechtenbaum 1, Sami Kolta 1, Giancarlo

Isaia 2, B Cannata Andia 3 and Jean-Pierre Devogelaer 4

1 University Paris-Descartes, France

2 University of Torino, Italy

3 University Central des Asturias, Spain

4 University of Louvain, Belgium

Abstract

Objectives: Early osteoporotic fractures have a great impact on the

disease progression, the first fracture being a major risk factor for

further fractures. Subsequently, the efficacy of antiosteoporotic

treatments in the younger women appears of utmost interest. Strontium

ranelate is an anti-osteoporotic treatment, simultaneously reducing

bone resorption while promoting bone formation. Its efficacy against

vertebral fractures is presently assessed in a subset of women aged 50

to 65 years.

Methods: SOTI was an international, double-blind, placebo-controlled

trial, supporting the efficacy of strontium ranelate 2g/day orally in

reducing the risk of vertebral fractures in postmenopausal women with

osteoporosis and a prevalent vertebral fracture. 353 of these

randomized women, aged 50 to 65 years were included in this analysis

over 4 years.

Results: Over 4 years, strontium ranelate significantly reduced the

risk of vertebral fracture by 35% (RR=0.65; 95%CI [0.42;0.99],

p<0.05). In the strontium ranelate group, the BMD mean change from

baseline increased by 15.8% at lumbar spine and 7.1% at femoral neck.

Conclusion: These data demonstrate a significant vertebral

antifracture efficacy of strontium ranelate in young postmenopausal

women with severe osteoporosis aged 50 to 65 years and confirms the

efficacy of this anti-osteoporotic treatment to prevent vertebral

fractures, whatever the age of the patients.

http://ard.bmj.com/cgi/content/abstract/ard.2008.094516v1?papetoc

--

Not an MD